Literature DB >> 21734186

Implication of microRNAs in atrial natriuretic peptide and nitric oxide signaling in vascular smooth muscle cells.

Kumar U Kotlo1, Bahar Hesabi, Robert S Danziger.   

Abstract

MicroRNAs (miRs) are endogenous small RNA molecules that suppress gene expression by binding to complementary sequences in the 3' untranslated regions of their target genes. miRs have been implicated in many diseases, including heart failure, ischemic heart disease, hypertension, cardiac hypertrophy, and cancers. Nitric oxide (NO) and atrial natriuretic peptide (ANP) are potent vasorelaxants whose actions are mediated through receptor guanylyl cyclases and cGMP-dependent protein kinase. The present study examines miRs in signaling by ANP and NO in vascular smooth muscle cells. miR microarray analysis was performed on human vascular smooth muscle cells (HVSMC) treated with ANP (10 nM, 4 h) and S-nitroso-N-acetylpenicillamine (SNAP) (100 μM, 4 h), a NO donor. Twenty-two shared miRs were upregulated, and 21 shared miRs were downregulated, by both ANP and SNAP (P < 0.05). Expression levels of four miRs (miRs-21, -26b, -98, and -1826), which had the greatest change in expression, as determined by microarray analysis, were confirmed by quantitative RT-PCR. Rp-8-Br-PET-cGMPS, a cGMP-dependent protein kinase-specific inhibitor, blocked the regulation of these miRs by ANP and SNAP. 8-bromo-cGMP mimicked the effect of ANP and SNAP on their expression. miR-21 was shown to inhibit HVSMC contraction in collagen gel lattice contraction assays. We also identified by computational algorithms and confirmed by Western blot analysis new intracellular targets of miR-21, i.e., cofilin-2 and myosin phosphatase and Rho interacting protein. Transfection with pre-miR-21 contracted cells and ANP and SNAP blocked miR-21-induced HVSMC contraction. Transfection with anti-miR-21 inhibitor reduced contractility of HVSMC (P < 0.05). The present results implicate miRs in NO and ANP signaling in general and miR-21 in particular in cGMP signaling and vascular smooth muscle cell relaxation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734186      PMCID: PMC3191566          DOI: 10.1152/ajpcell.00088.2011

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  71 in total

Review 1.  The therapeutic potential of microRNA modulation.

Authors:  Aimee Jackson; Peter S Linsley
Journal:  Discov Med       Date:  2010-04       Impact factor: 2.970

Review 2.  MicroRNAs and pharmacogenomics.

Authors:  Noam Shomron
Journal:  Pharmacogenomics       Date:  2010-05       Impact factor: 2.533

Review 3.  MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems.

Authors:  Héctor Herranz; Stephen M Cohen
Journal:  Genes Dev       Date:  2010-07-01       Impact factor: 11.361

Review 4.  miRNAs as therapeutic targets in ischemic heart disease.

Authors:  Robert J A Frost; Eva van Rooij
Journal:  J Cardiovasc Transl Res       Date:  2010-03-30       Impact factor: 4.132

5.  Evidence for cross-talk between atrial natriuretic peptide and nitric oxide receptors.

Authors:  Kumar U Kotlo; Mark M Rasenick; Robert S Danziger
Journal:  Mol Cell Biochem       Date:  2009-12-19       Impact factor: 3.396

6.  Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism.

Authors:  Felix Fleissner; Virginija Jazbutyte; Jan Fiedler; Shashi K Gupta; Xiaoke Yin; Qingbo Xu; Paolo Galuppo; Susanne Kneitz; Manuel Mayr; Georg Ertl; Johann Bauersachs; Thomas Thum
Journal:  Circ Res       Date:  2010-05-20       Impact factor: 17.367

Review 7.  MicroRNA-21 in cardiovascular disease.

Authors:  Yunhui Cheng; Chunxiang Zhang
Journal:  J Cardiovasc Transl Res       Date:  2010-05-01       Impact factor: 4.132

Review 8.  MicroRNAs in vascular biology and vascular disease.

Authors:  Chunxiang Zhang
Journal:  J Cardiovasc Transl Res       Date:  2010-02-13       Impact factor: 4.132

Review 9.  Microprocessor of microRNAs: regulation and potential for therapeutic intervention.

Authors:  Kevin J Beezhold; Vince Castranova; Fei Chen
Journal:  Mol Cancer       Date:  2010-06-01       Impact factor: 27.401

Review 10.  Novel functions for small RNA molecules.

Authors:  Chunxiang Zhang
Journal:  Curr Opin Mol Ther       Date:  2009-12
View more
  15 in total

1.  Effect of nitric oxide on microRNA-155 expression in human hepatic epithelial cells.

Authors:  Yael Yuhas; Eva Berent; Shai Ashkenazi
Journal:  Inflamm Res       Date:  2014-04-01       Impact factor: 4.575

2.  Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy.

Authors:  Kuan-Lu Fan; Hai-Feng Zhang; Jie Shen; Qi Zhang; Xin-Li Li
Journal:  Indian Heart J       Date:  2012-12-28

Review 3.  Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders.

Authors:  F V Brozovich; C J Nicholson; C V Degen; Yuan Z Gao; M Aggarwal; K G Morgan
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

Review 4.  MicroRNAs in hypertension: mechanisms and therapeutic targets.

Authors:  Sándor Bátkai; Thomas Thum
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

5.  DiGeorge syndrome critical region 8 (DGCR8) protein-mediated microRNA biogenesis is essential for vascular smooth muscle cell development in mice.

Authors:  Zixuan Chen; Jianmin Wu; Chuanhe Yang; Pei Fan; Louisa Balazs; Yan Jiao; Meifeng Lu; Weikuan Gu; Chengyao Li; Lawrence M Pfeffer; Gabor Tigyi; Junming Yue
Journal:  J Biol Chem       Date:  2012-04-17       Impact factor: 5.157

Review 6.  Hypertension: Potential Player in Cardiovascular Disease Incidence in Preeclampsia.

Authors:  Parya Amini; Mehran Amrovani; Zohre Saleh Nassaj; Parisa Ajorlou; Aiyoub Pezeshgi; Bahareh Ghahrodizadehabyaneh
Journal:  Cardiovasc Toxicol       Date:  2022-03-28       Impact factor: 3.231

7.  Hydrogen Sulfide Therapy Suppresses Cofilin-2 and Attenuates Ischemic Heart Failure in a Mouse Model of Myocardial Infarction.

Authors:  Khoa Nguyen; Vinh Q Chau; Adolfo G Mauro; David Durrant; Stefano Toldo; Antonio Abbate; Anindita Das; Fadi N Salloum
Journal:  J Cardiovasc Pharmacol Ther       Date:  2020-05-11       Impact factor: 2.457

8.  Concentration-related effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility.

Authors:  W Michael Dismuke; Jin Liang; Darryl R Overby; W Daniel Stamer
Journal:  Exp Eye Res       Date:  2013-12-27       Impact factor: 3.467

9.  Identification of micro-RNA networks in end-stage heart failure because of dilated cardiomyopathy.

Authors:  Xiaoming Zhu; Hongjiang Wang; Fan Liu; Li Chen; Weijia Luo; Pixiong Su; Weiming Li; Liping Yu; Xinchun Yang; Jun Cai
Journal:  J Cell Mol Med       Date:  2013-09-02       Impact factor: 5.310

10.  The C2238/αANP variant is a negative modulator of both viability and function of coronary artery smooth muscle cells.

Authors:  Speranza Rubattu; Simona Marchitti; Franca Bianchi; Sara Di Castro; Rosita Stanzione; Maria Cotugno; Cristina Bozzao; Sebastiano Sciarretta; Massimo Volpe
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.